What Ferrum Lek (Iron Dextran) Treats: Main Uses and Benefits

---

Treating Iron Deficiency Unresponsive to Oral Therapy

Ferrum Lek is generally used for managing severe Iron Deficiency Anemia (IDA) in patients who are either intolerant to oral iron supplements or have had an unsatisfactory therapeutic response. This parenteral approach is commonly used for iron replacement of the iron needed to produce hemoglobin, which helps manage the underlying deficiency that oral treatment cannot effectively address.

---

Easing Systemic Fatigue and Functional Strain

The medication is applied in addressing symptoms related to systemic imbalance, specifically the chronic fatigue, generalized weakness, and noticeable physiological strain caused by poor oxygen transport. It is relevant for conditions presenting with disruptive symptom manifestations, including those caused by malabsorption syndromes, chronic blood loss, or Chronic Kidney Disease (CKD). By supporting the repletion of the body's iron stores, it supports the recovery of oxygen delivery capacity.

“This approach is relevant in contexts involving heightened systemic burden where oral iron delivery is not possible or sufficient.”

This may support improved physical stamina and contributes to easing fatigue, supporting general well-being during symptomatic phases, and assisting with maintaining functional stability.

---

Symptom Management Focus

Therapeutic Focus	Indication Example	Symptom Eased
Primary Indication	Severe Iron Deficiency Anemia (IDA)	Chronic Fatigue & Weakness
Contextual Use	Iron Malabsorption Syndromes	Reduced Physical Stamina
Patient Group	CKD / Chronic Blood Loss	Shortness of Breath (Exertional)

Regulatory References

1. Iron Dextran Injection Labeling DailyMed (NIH/NLM)

Who Can and Cannot Use Ferrum Lek (Iron Dextran)?

Official regulatory information defines the populations eligible for Iron Dextran based strictly on medical necessity and contraindication status.

Contraindicated Populations

The medicine is contraindicated and must not be used in specific groups as defined by official labeling:

• Patients with a history of hypersensitivity to iron dextran or any component of the formulation.
• Individuals with anemias not attributed to iron deficiency (e.g., non-iron deficiency related anemias).
• Patients showing evidence of iron overload (e.g., hemosiderosis) or experiencing the acute phase of infectious kidney disease.

---

Eligibility by Age and Condition

Population Group	Regulatory Status
Eligible Adults/Children	Approved for documented iron deficiency where oral iron has failed or is intolerable.
Infants under 4 months	Not recommended for use.
Pregnancy Status	Restricted Use (Category C); permitted only if the benefit justifies the potential risk.
Serious Hepatic/Cardiac Impairment	Use requires extreme caution and close monitoring.
Rheumatoid Arthritis/Allergies	Use requires caution due to potential for exacerbation or hypersensitivity risk.

Eligibility is limited to those who meet the criteria for severe iron deficiency and do not possess any of the listed contraindications or high-risk comorbidities.

Ferrum Lek (Iron Dextran) Interactions with Other Medicines and Products

This section details the clinically significant interactions of Iron Dextran as outlined in official regulatory and prescribing information.

---

Documented Interaction Patterns

Interacting Substance/Class	Official Interaction Description
Oral Iron Supplements	Concurrent use is generally avoided as it may reduce the absorption of the oral iron and poses a risk of iron overload.
Other Parenteral Iron	Avoided due to the potential for excessive iron accumulation (iatrogenic hemosiderosis).
ACE Inhibitors (e.g., Enalapril)	Concomitant administration may increase the risk for serious anaphylactic-type reactions.
Oral Tetracycline & Quinolone Antibiotics	Iron Dextran can interfere with the systemic absorption of these oral antibiotics.
Chloramphenicol	May delay the body's expected therapeutic response to parenteral iron treatment.

---

Procedural and Testing Constraints

• Laboratory Tests: High doses of Iron Dextran can interfere with specific tests. Serum iron determinations may be unreliable for up to three weeks after administration, and the drug can cause falsely elevated serum bilirubin and falsely decreased serum calcium values.
• Population Cautions: Patients with a history of significant allergies or severe liver impairment should use Iron Dextran with extreme care, as interactions may be amplified in these groups. Administration may also exacerbate joint symptoms in those with rheumatoid arthritis.

Targeted Delivery via the Reticuloendothelial System (RES)

The mechanism is initiated by the Reticuloendothelial System (RES) macrophages which recognize and internalize the Iron Dextran complex. Inside the cell, an acidic environment cleaves the protective dextran ligand, releasing the iron, which is then handled by the subsequent physiological transport proteins. This process utilizes the RES pathway rather than the intestinal absorption pathway.

---

Homeostatic Transport and Storage Restoration

Once released, the iron is exported from the macrophage and rapidly bound by the transport protein Transferrin, thereby increasing the saturation of circulating Transferrin. Simultaneously, iron not immediately required for synthesis is utilized to synthesize storage proteins (Ferritin), contributing to changes in the systemic iron homeostasis pathway parameters.

---

Substrate Provision for Erythropoiesis

The Transferrin-iron complex delivers the necessary Fe^3+ substrate to erythroid precursor cells in the bone marrow, where it is utilized to synthesize Heme and, ultimately, functional Hemoglobin (Hb). This mechanism ensures the immediate availability of the core component required and results in the synthesis of functional Hemoglobin, the molecule responsible for oxygen transport.

How to Use Ferrum Lek (Iron Dextran)

Ferrum Lek is an injectable solution (parenteral iron) that must be administered strictly according to established protocols, focusing on the method of administration, required observation periods, and precise dosing. This medicine is not for self-administration and must only be given by or under the direct supervision of a doctor or a trained health professional.

Administration Details

Domain	Instruction Guideline
Route	Intravenous (IV) injection or Intramuscular (IM) injection.
Preparation	The solution is ready-to-use; however, it may be diluted in 0.9% sodium chloride solution for immediate IV use.
Concurrent Use	Do not take any other iron supplements (oral, nonprescription, or herbal) while receiving this medication, unless directed by your healthcare provider.

Dosing and Procedural Steps

The total required dose is calculated by the healthcare provider based on a formula involving the patient's body weight and the difference between the observed and desired hemoglobin (Hb) levels. The daily dose is strictly limited and must not exceed 2 mL (which is 100 mg of elemental iron).

1. Test Dose: A small test dose (e.g., 0.5 mL) must be administered first to assess tolerance.
2. Observation: The patient must be monitored for a minimum of 1 hour following the test dose before the full treatment can proceed.
3. Full Dose: If the test dose is tolerated, the remainder of the prescribed dose is administered. This daily dose is repeated until the full calculated total iron requirement has been met.

Research evidence / Overview of studies for Ferrum Lek (Iron Dextran)

---

Evidence for Use in Iron Deficiency Anemia (IDA) Where Oral Iron Has Failed

Research exploring Iron Dextran has been conducted primarily in the context of Iron Deficiency Anemia (IDA), particularly for people who either cannot tolerate iron supplements taken by mouth or whose condition has not responded adequately to oral treatment. The research landscape includes Randomized Controlled Trials (RCTs) and meta-analyses to compile findings from multiple trials. These study designs were applied in research contexts that included patients with fluctuating or unstable symptoms of iron deficiency.

In these studies, researchers monitored several outcomes, focusing heavily on hematologic biomarkers to evaluate changes in iron status. They tracked changes in Hemoglobin (Hb) concentration, the protein in red blood cells that carries oxygen, and Serum Ferritin, which measures the body's stored iron. Studies compared how these key markers evolved in patients receiving Iron Dextran versus those receiving oral iron or in comparative trials involving other intravenous iron preparations. Studies report how symptoms evolved in the observed populations, and studies reported measurements of the patterns of change in these biomarkers shortly after administration.

Long-term outcomes regarding the durability of the iron repletion in all populations are not well characterized. Data for certain groups remain insufficient regarding extended follow-up.

---

Research on Functional Status and Symptomatic Iron Deficiency

Research has also explored outcomes related to systemic or functional imbalance, such as fatigue, by evaluating how symptoms change over time. These studies monitored outcomes reflecting daily functioning or activity level, as iron deficiency can present with generalized weakness and physiological strain. Research has explored the use of parenteral iron, including Iron Dextran, in individuals who may be iron deficient but not yet fully anemic, to see how functional status was measured following iron repletion.

Systematic reviews that combine trial data described patterns where shifts in physical function metrics and standardized fatigue scores were measured in some iron-deficient adults receiving parenteral iron, compared to placebo groups. Systematic reviews also reported that findings for overall quality of life scores across the studied cohorts were mixed or inconclusive.

---

Evidence in Special Populations

Research has explored the use of Iron Dextran in several specific groups where iron deficiency is common. These include studies involving patients with Chronic Kidney Disease (CKD), who often require intravenous iron due to the complexity of their condition. Data show patterns related to the measured shifts in iron stores and hemoglobin levels when Iron Dextran was studied in anemia-related cohorts.

Other research contexts involved populations with conditions marked by functional limitations and malabsorption. Furthermore, the medicine has been evaluated in studies examining pregnant women with moderate to severe IDA. It is important to note that results apply only to the populations studied, and data for certain groups remain insufficient compared to the broader adult research base.

Key Studies & References

1. Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women: a Randomized Controlled Trial (NCT03212781)
2. The Effect of Parenteral or Oral Iron Supplementation on Fatigue, Sleep, Quality of Life and Restless Legs Syndrome in Iron-Deficient Blood Donors: A Secondary Analysis of the IronWoMan RCT

Common questions about Ferrum Lek (Iron Dextran) (FAQ)

---

Q: Is this a one-time injection, or will I need to come back for multiple doses?

According to official product information, this is not typically a single-dose administration. The total dose is determined by your healthcare provider and may require multiple administrations until the full calculated iron requirement has been met.

---

Q: Can I give myself the injection at home?

Regulatory documents state that this injectable medicine is not for self-administration. The product labeling indicates that administration should only be performed by, or under the direct supervision of, a trained healthcare professional.

---

Q: What happens if the medicine accidentally freezes?

Official labeling specifies required storage conditions to maintain the stability of the medicine. The medicine should be stored at or below 25 C (77 F), and freezing should be avoided to help ensure product quality and stability.

How to Store and Dispose of Ferrum Lek (Iron Dextran)?

Official regulatory guidelines dictate specific requirements for storing and discarding Ferrum Lek (Iron Dextran) to maintain its stability and ensure public safety.

Mandatory Storage Conditions

Requirement	Rule Defined by Labeling
Temperature	Store at or below 25 C (77 F). Do not freeze the solution.
Protection	Keep the product in the original packaging to protect it from light.
Child Safety	Must be kept out of the sight and reach of children.
Stability	Vials are for single use; any unused portion must be immediately discarded.

Official Disposal Instructions

Expired or unused Ferrum Lek must be disposed of according to local regulatory requirements for pharmaceutical waste. The medicine must not be thrown away with household trash or poured into wastewater, which prevents environmental contamination.